Creative Biolabs Expands Liposomal Delivery Services to Address Formulation Challenges

Liposomes continue to represent the most successful drug delivery system to date, effectively addressing challenges such as low solubility, stability in serum, circulation half-life, biodistribution, and target tissue selectivity. However, researchers face significant obstacles in selecting appropriate lipids and achieving sufficient encapsulation efficiency without compromising stability. Creative Biolabs is expanding its liposomal formulation and encapsulation services as a direct response to these challenges, enhancing capabilities across multiple therapeutic classes.

The company's expanded services include specialized liposomal formulations for proteins and peptides, focusing on the relationship between encapsulation efficiency and factors such as phospholipid composition, buffer concentration, incubation time, incubation temperature, and drug loading to develop optimal formulations. For small-molecule drugs, particularly in oncology and central nervous system applications where compounds are often highly hydrophobic, dose-limited by toxicity, or unable to accumulate in target tissues, liposomal encapsulation offers solutions to improve solubility, reduce systemic exposure, and fine-tune biodistribution.

Creative Biolabs employs two principal methods to encapsulate small molecules within liposomes—passive loading and active loading—each suited to specific types of compounds and applications. The company also provides formulation safety evaluation services that rigorously examine biocompatibility and potential cytotoxicity to ensure formulations meet the highest standards for research use. As vaccine design becomes more sophisticated, the company offers liposome-based adjuvant development services that allow developers to integrate immunostimulants—such as MPLA, QS‑21, or TLR agonists—into customizable lipid structures that can shape immune responses with greater precision.

These expanded services address what the company describes as the 'last-mile problem' in liposomal delivery, where formulation challenges can prevent promising therapeutic candidates from reaching their full potential. By providing comprehensive support across different therapeutic categories, Creative Biolabs aims to help researchers overcome the technical hurdles that have limited broader adoption of liposomal delivery systems. The company's approach combines scientific expertise with practical formulation strategies to create solutions tailored to specific drug properties and therapeutic goals. More information about these services is available at https://www.creative-biolabs.com/lipid-based-delivery/.